Benzinga · Feb 24, 2026
XO
NASDAQ · XOMA
XOMA Royalty Corp.
Healthcare · Biotechnology
$40.17
Up+$0.00 (+0.00%)
Updated Sep 11, 2026, 8:05 PM
SID Score
6.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 318.12M
- P/E ratio
- 16.64
- Dividend yield
- 0.00%
- 52-week range
- $25.72 – $45.22
- Volume
- 6.71M
- Avg. volume
- 54.05K
Price performance
XOMA price history
1M range · 0 trading sessions · Daily adjusted prices
XOMA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest XOMA news
The latest Smart Investors Daily articles mentioning XOMA.
Stock researchCompany · Overview
XOMA research
Overview
Company profile and research snapshot.
Company profile
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $72.67
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 30, 2026 | HC Wainwright & Co. | Neutral | — |
| Mar 20, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 24, 2026 | Leerink Partners | Outperform | — |
| Dec 11, 2025 | Leerink Partners | Outperform | — |
| Dec 11, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 24, 2026
Leerink Partners Maintains Outperform on XOMA Royalty, Raises Price Target to $50
Leerink Partners analyst Jason Zhuang maintains XOMA Royalty (NASDAQ:XOMA) with a Outperform and raises the price target from $45 to $50.
Yahoo · Jan 5, 2026
Implied Volatility Surging for XOMA Royalty Stock Options
Investors need to pay close attention to XOMA stock based on the movements in the options market lately.
globenewswire.com · Nov 21, 2025
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding common shares of LAVA Therapeutics N.V.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
